A detailed history of Mwa Asset Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Mwa Asset Management holds 2,583 shares of VRTX stock, worth $1.28 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares
2,583
Previous 4,601 43.86%
Holding current value
$1.28 Million
Previous $2.16 Billion 44.3%
% of portfolio
0.8%
Previous 1.54%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

SELL
$460.0 - $505.78 $928,280 - $1.02 Million
-2,018 Reduced 43.86%
2,583 $1.2 Billion
Q2 2024

Jul 26, 2024

BUY
$392.81 - $485.53 $978,489 - $1.21 Million
2,491 Added 118.06%
4,601 $2.16 Billion
Q1 2024

May 08, 2024

SELL
$407.69 - $446.08 $40,361 - $44,161
-99 Reduced 4.48%
2,110 $882 Million
Q4 2023

Jan 23, 2024

BUY
$343.0 - $410.68 $346,773 - $415,197
1,011 Added 84.39%
2,209 $899 Million
Q3 2023

Oct 27, 2023

BUY
$338.18 - $362.46 $405,139 - $434,227
1,198 New
1,198 $417 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $127B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Mwa Asset Management Portfolio

Follow Mwa Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mwa Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Mwa Asset Management with notifications on news.